AI assistant
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012
Nov 21, 2012
29977_dirs_2012-11-21_eff4ebb2-40c6-4aae-98fa-fdb34eccc9d3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-11-20
Reporting Person: STAHL NEIL (SVP Res and Devel Sciences)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-11-20 | Common Stock | M | 17000.0 | $16.8 | Acquired | 76121.0 | Direct |
| 2012-11-20 | Common Stock | F | 1708.0 | $167.17 | Disposed | 74413.0 | Direct |
| 2012-11-20 | Common Stock | F | 7694.0 | $167.17 | Disposed | 66719.0 | Direct |
| 2012-11-20 | Common Stock | M | 37500.0 | $16.8 | Acquired | 104219.0 | Direct |
| 2012-11-20 | Common Stock | F | 3768.0 | $167.17 | Disposed | 100451.0 | Direct |
| 2012-11-20 | Common Stock | F | 16973.0 | $167.17 | Disposed | 83478.0 | Direct |
| 2012-11-21 | Common Stock | S | 9200.0 | $173.8 | Disposed | 74278.0 | Direct |
| 2012-11-21 | Common Stock | S | 13157.0 | $174.47 | Disposed | 61121.0 | Direct |
| 2012-11-21 | Common Stock | S | 2000.0 | $175.49 | Disposed | 59121.0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-11-20 | Non-Qualified Stock Option (right to buy) | $16.8 | M | 17000.0 | Disposed | 2018-12-17 | Common Stock (17000.0) | Direct |
| 2012-11-20 | Non-Qualified Stock Option (right to buy) | $16.8 | M | 37500.0 | Disposed | 2018-12-17 | Common Stock (37500.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5479.0 | Indirect |
Footnotes
F1: Represents volume-weighted average price of sales of 9,200 shares of Company stock on November 21, 2012 at prices ranging from $173.17 to $173.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 21, 2012 at each separate price.
F2: Represents volume-weighted average price of sales of 13,157 shares of Company stock on November 21, 2012 at prices ranging from $174.00 to $174.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 21, 2012 at each separate price.
F3: Represents volume-weighted average price of sales of 2,000 shares of Company stock on November 21, 2012 at prices ranging from $175.00 to $175.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 21, 2012 at each separate price.
F4: The option became exercisable with respect to all shares underlying the option on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011.
F5: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
F6: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.